Brownlie Keith L 4
4 · Celldex Therapeutics, Inc. · Filed Jun 17, 2022
Insider Transaction Report
Form 4
Brownlie Keith L
Director
Transactions
- Award
Non-Qualified Stock Option (right to buy)
2022-06-16+13,600→ 13,600 totalExercise: $22.48From: 2023-06-16Exp: 2032-06-16→ Common Stock (13,600 underlying)
Footnotes (1)
- [F1]Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.